KIT mutation

Thanks Dr Loghavi. So you will not typically see atypical mast cell aggregates in CBF AML with c-kit mutation? (@manupandey27)

•KIT/PDGFRA mutations in metastatic, imatinib-resistant #GIST •Prior Tx selects for resistant A-loop mutations •ctDNA resistance mutations prognosticate efficacy of 3rd/4th-line TKI @Annals_Oncology @DrCeSarcoma @SteveBialickDO @seppobauer S. George https://t.co/Mgzutsu317 (@JTrentMDPhD)

Practically I would be getting a BMT consult. Conceptually I get comfort from not transplanting favorable risk ELN because the CR2 rate is still high. Even Kit mutations make CBF AML less favorable, with del7, I’d be concerned (@TheDoctorIsVin)

Molecularly matched therapy (MMT) was given in 2009 :) This is my first MMT case-thymic carcinoma with C-KIT mutation . (@UmutDisel)

#ASH22 #leusm Hyak: c-Kit mutations assoc w decreased DFS (and possibly OS) in CBF AML if VAF >10% but not if <10%. FLT3 and Ras mutations had no impact on survival outcomes. (@hemedoc)

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma. @FilipJankuMD @UTHealthSAMDA #melsm https://t.co/0HDoC88Nm5 (@OncLive)

The efficacy seen with ripretinib in patients with KIT-mutated melanoma was higher than has been previously reported @FilipJankuMD @UTHealthSAMDA #melsm https://t.co/AxIs2YBpl7 (@OncLive)

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma @FilipJankuMD @UTHealthSAMDA #melsm https://t.co/ZRxXWkpXAZ (@OncLive)

Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor #GIST harboring heterogenous KIT/PDGFRA mutations ⁦@seppobauer⁩ ⁦@schoffski⁩ ⁦@jeanyvesblay⁩ ⁦@GinaDAmatoMD1⁩ ⁦@SylvesterCancer⁩ https://t.co/rwLy6Gh01X (@JTrentMDPhD)

Open @MDAndersonNews #ClinicalTrial #2021-0331 Study of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Vs Placebo in Pts W/ Indolent Systemic Mastocytosis | PI: Prithviraj Bose @bose_prithviraj | NCT03731260 | https://t.co/JiwPVibHwR #leusm (@Lisa_Palacios)

Today is #GISTAwarenessDay. #GIST is a sarcoma of the GI tract. Despite common misbeliefs, this cancer is not always easily cured, treatment is not 1 size fits all, KIT mutations are not the only drivers, & it’s not as rare as we once believed. (@JasonSicklick)

Thank you sir. These were my thoughts too. But, I wanted to recheck the literature once before commenting and found this nice article showing no adverse impact of c-kit mutation in children with t(8;21) AML. https://t.co/HI9fW9n7AV (@nitsoccer)

Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations. @schoffski @KU_Leuven @ctosociety #CTOS2020 #scmsm https://t.co/rSSRzRCj66 (@OncLive)

Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST @schoffski @KU_Leuven #scmsm https://t.co/VfRXsIyFEk (@OncLive)

Our latest: RAS/MAPK Alterations Are Associated with KIT Mutations in Germ-cell Tumors and May Have Therapeutic Implications https://t.co/GHBSAdqC5S @MLadanyi @DrDarrenFeldman @jamalbenhamida @CDebyaniPhD (@DouglasMataMD)

A Comparison of Clinical and Molecular Characteristics of Patients With Systemic Mastocytosis With Chronic Myelomonocytic Leukemia to CMML Alone | Kit mutations are pathognomonic of SM| ⁦@sanamloghavi⁩ ⁦@DavidSteensma⁩ ⁦@HoratiuOlteanu⁩ https://t.co/DIwhBMZ7FI (@MrinalPatnaik)

NET not GIST. Only case reports of Glivec working in NETs with KIT mutations. (@SiBucz)